211 filings
Page 6 of 11
8-K
gk4v602 2j8v1n
27 May 20
Mersana Therapeutics Reports Positive Interim Data from the Expansion Portion of the XMT-1536 Phase 1 Study
6:30am
EFFECT
bkfpf4ic hk
18 May 20
Notice of effectiveness
12:15am
8-K
5klbviwg6hkyrs931xq
14 May 20
Mersana Therapeutics Announces Initiation of XMT-1592 Phase 1 Dose
4:15pm
UPLOAD
mcnwmjv rt
13 May 20
Letter from SEC
12:00am
CORRESP
2613z8 sg
13 May 20
Correspondence with SEC
12:00am
8-K
9p0b gk33mv
8 May 20
Mersana Therapeutics Announces First Quarter 2020 Financial Results and Provides Business Update
6:31am
DEFA14A
krms6xq6mjqoafj6bi41
20 Apr 20
Additional proxy soliciting materials
6:09am
8-K
kn1s4ik
15 Apr 20
Mersana Therapeutics Announces Appointment of Martin H. Huber, M.D., to Board of Directors
8:15am
424B5
1m8b627d
9 Apr 20
Prospectus supplement for primary offering
4:10pm
8-K
9ddp95itk42xmcadix
8 Apr 20
Other Events
8:30am
8-K
y2rzzz fjklrhc7
30 Mar 20
Mersana Therapeutics Reports Updated Data from the XMT-1536 Phase 1 Dose Escalation Study
4:15pm
8-K
v4ckfi
20 Mar 20
Mersana Therapeutics to Report Updated Data from the XMT-1536 Phase 1 Dose
9:38am
CT ORDER
wgreq33o0lrsjl3v
17 Mar 20
Confidential treatment order
9:23am
8-K
20cbpy6 hrvyj82nc6do
16 Mar 20
Entry into a Material Definitive Agreement
8:00am
S-8
7tli6h3
28 Feb 20
Registration of securities for employees
4:39pm
8-K
teepvbgctkuyu8a3h
28 Feb 20
Mersana Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Updates
6:15am